Summary
Johnson & Johnson has traded under pressure for most of the year and the stock is still in the red on a YTD basis.
But the turnaround in share prices since the beginning of June suggests a major bullish reversal could be in the works.
This well-diversified healthcare company offers market protection for investors on several levels.
JNJ's elevated dividend currently yield (2.68%) and low valuation put the stock in an excellent position to move higher into the final parts of this year.
Johnson & Johnson (JNJ) has traded under pressure for most of the year. The stock as lost -3.76% on a YTD basis, despite strong earnings results that were posted during the second quarter. For many investors, the market activity here comes as something of a surprise, given the company’s position in the industry and its incredible ability to generate free cash flow (even in choppy market environments). But these latest earnings results should remove many of those concerns, and the stock looks to be on the verge of a breakout above its March 12th highs at 135.70. Here, we will look at some of the recent highlights which should be encouraging for long investors holding JNJ for its elevated dividend payouts of 2.68%.
